ClinicalTrials.gg
CompletedNCT05970289Updated Oct 20, 2026

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

A Phase 2 interventional study of PEG-IFNα and BRII-835 in Chronic Hepatitis B Virus Infection, sponsored by Brii Biosciences Limited. Completed at 28 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.
Updated Oct 20, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
181st of 274
86 · median 120
Started
2023
with 28 others
Phase 2
72 of 378
15 open now
Registered
272nd of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 181st largest by enrollment of the 274 interventional ones that give a count, is one of 29 that started in 2023, is one of 72 in phase 2, and was the 272nd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

03

Conditions studied

  • Chronic Hepatitis B Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-60.
  • ≥ 18 kg/m2 and ≤ 32 kg/m2.
  • Chronic infection for ≥ 6 months.
  • On NRTI therapy for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the participant unsuitable for participation.
  • Significant liver fibrosis or cirrhosis.
  • History or evidence of drug or alcohol abuse.
  • History of intolerance to SC injection.
  • History of chronic liver disease from any cause other than chronic infection.
  • History of hepatic decompensation.
  • to the use of Peg-IFNα.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive multiple doses of PEG-IFNα for 48 weeks.

    Biological: PEG-IFNα

  • Experimental
    Cohort 2

    Participants will receive multiple doses of higher dose level of BRII-835 + PEG-IFNα for 48 weeks.

    Biological: PEG-IFNα · Drug: BRII-835

  • Experimental
    Cohort 3

    Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks.

    Biological: PEG-IFNα · Drug: BRII-835

  • Experimental
    Cohort 4

    Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks (participants who received BRII-179 in a previous study will roll over into this cohort).

    Biological: PEG-IFNα · Drug: BRII-835

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with HBsAg loss at end of treatment

    Time frame: Up to Week 48

  2. Proportion of participants with HBsAg loss at 24 weeks post-end of treatment

    Time frame: Up to Week 72

  3. Proportion of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to Week 72

  4. Proportion of participants with serious adverse events (SAEs)

    Time frame: Up to Week 72

07

Study locations

28 sites
  • Investigative Site 61001
    Kingswood, New South Wales 2747, Australia
  • Investigative Site 61002
    Birtinya, Queensland 4575, Australia
  • Investigative Site 61003
    Melbourne, Victoria 3004, Australia
  • Investigative Site 86001
    Beijing, Beijing Municipality 100000, China
  • Investigative Site 86007
    Beijing, Beijing Municipality 100069, China
  • Investigative Site 86004
    Chongqing, Chongqing Municipality 400010, China
  • Investigative Site 86006
    Guangzhou, Guangdong 510630, China
  • Investigative Site 85201
    Hong Kong, HONG KONG 999077, China
  • Investigative Site 85202
    Hong Kong, HONG KONG 999077, China
  • Investigative Site 86008
    Changchun, Jilin 130021, China
  • Investigative Site 86013
    Shanghai, Shanghai Municipality 200025, China
  • Investigative Site 88601
    Kaohsiung, Taiwan 80756, China
  • Investigative Site 88602
    Taipei, Taiwan 10041, China
  • Investigative Site 88603
    Taipei, Taiwan 11217, China
  • Investigative Site 86011
    Hangzhou, Zhengjiang 310016, China
  • Investigative Site 65001
    Singapore, Singapore 169856, Singapore
  • Investigative Site 65002
    Singapore, Singapore 529889, Singapore
  • Investigative Site 82001
    Busan, Busan 49241, South Korea
  • Investigative Site 82002
    Chuncheon, CHUNCHEON-SI 24253, South Korea
  • Investigative Site 82004
    Daegu, Daegu 41566, South Korea
  • Investigative Site 82003
    Seoul, Seoul 6351, South Korea
  • Investigative Site 82005
    Seoul, 13496, South Korea
  • Investigative Site 82006
    Soeul, 05505, South Korea
  • Investigative Site 66003
    Bangkok, Bangkok 10330, Thailand
  • Investigative Site 66005
    Khon Kaen, Changwat Khon Kaen 40002, Thailand
  • Investigative Site 66006
    Nonthaburi, Changwat Nonthaburi 11000, Thailand
  • nvestigative Site 66007
    Chiang Mai, 50200, Thailand
  • Investigative Site 66008
    Songkhla, 90110, Thailand
08

References and documents

Publications

  • Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, Tangkijvanich P, Lim YS, Dai CY, O'Beirne J, Weltman M, Khemnark S, Piratvisuth T, Manasirisuk W, Chen X, Liu CJ, Heo J, Lee J, Niu J, Kumar R, Kumar R, Zhu C, Cao K, Tian A, Chen X, Zhu Q, Margolis D, Jia J, Hong Z. Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial. Nat Med. 2026 Jan;32(1):151-159. doi: 10.1038/s41591-025-04049-z. Epub 2025 Nov 7. PubMed 41203919 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2025, 22 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 22 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Aug 22, 2023
Primary completionActual
Jul 16, 2025
CompletionActual
Jan 23, 2026was Feb 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Sites
9 sites added, 10 sites removed
Show 9 added (4 South Korea, 3 Thailand, 2 Singapore)
  • Investigative Site 65001 · Singapore, Singapore
  • Investigative Site 65002 · Singapore, Singapore
  • Investigative Site 82001 · Busan, South Korea
  • Investigative Site 82002 · Chuncheon, South Korea
  • Investigative Site 82004 · Daegu, South Korea
  • Investigative Site 82003 · Seoul, South Korea
  • Investigative Site 66003 · Bangkok, Thailand
  • Investigative Site 66005 · Khon Kaen, Thailand
  • Investigative Site 66006 · Nonthaburi, Thailand
Show 10 removed
  • Investigative Site 86001 · Beijing, China
  • Investigative Site 65001 · Singapore, Singapore
  • Investigative Site 65002 · Singapore, Singapore
  • Investigative Site 82002 · Chuncheon, South Korea
  • Investigative Site 82001 · Busan, South Korea
  • Investigative Site 82004 · Daegu, South Korea
  • Investigative Site 82003 · Seoul, South Korea
  • Investigative Site 66003 · Bangkok, Thailand
  • Investigative Site 66005 · Khon Kaen, Thailand
  • Investigative Site 66006 · Nonthaburi, Thailand
Oct 20, 2026
Study completion
Feb 2026→Jan 23, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    9 sites added, 10 sites removed
    Show 9 added (4 South Korea, 3 Thailand, 2 Singapore)
    • Investigative Site 65001 · Singapore, Singapore
    • Investigative Site 65002 · Singapore, Singapore
    • Investigative Site 82001 · Busan, South Korea
    • Investigative Site 82002 · Chuncheon, South Korea
    • Investigative Site 82004 · Daegu, South Korea
    • Investigative Site 82003 · Seoul, South Korea
    • Investigative Site 66003 · Bangkok, Thailand
    • Investigative Site 66005 · Khon Kaen, Thailand
    • Investigative Site 66006 · Nonthaburi, Thailand
    Show 10 removed
    • Investigative Site 86001 · Beijing, China
    • Investigative Site 65001 · Singapore, Singapore
    • Investigative Site 65002 · Singapore, Singapore
    • Investigative Site 82002 · Chuncheon, South Korea
    • Investigative Site 82001 · Busan, South Korea
    • Investigative Site 82004 · Daegu, South Korea
    • Investigative Site 82003 · Seoul, South Korea
    • Investigative Site 66003 · Bangkok, Thailand
    • Investigative Site 66005 · Khon Kaen, Thailand
    • Investigative Site 66006 · Nonthaburi, Thailand
    Study completion Feb 2026→Jan 23, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05970289
Lead sponsor
Brii Biosciences Limited
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 22, 2023
Primary completion
Jul 16, 2025
Completion
Jan 23, 2026
Last update
Oct 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegylated Interferon Alfa

Start the discussion